Larry G. Edwards - 31 Jan 2022 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO

Role: Chief Executive Officer
Signature: /s/ Larry Edwards
Issuer symbol: N/A
Transactions as of: 31 Jan 2022
Net transactions value: +$16,411
Form type: 4
Filing time: 02 Feb 2022, 18:21:05 UTC
Previous filing: 19 Jan 2022
Next filing: 17 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LJPC	Common Stock	Award	$16,411	+4,170	+68%	$3.94	10,308	31 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LJPC	Employee Stock Option (Right to Buy)	Award	$0	+4,170		$0.000000	4,170	31 Jan 2022	Common Stock	4,170	$4.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired on 1/31/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.